Conditioning solid tumor microenvironment through inflammatory chemokines and S100 family proteins

Cancer Letters

Volumn 365, Issue 1, 2015, Pages 11-22

  Nasser, Mohd W ^a   Elbaz, Mohamad ^a   Ahirwar, Dinesh K ^a   Ganju, Ramesh K ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Chemokines; S100 proteins; Tumor microenvironment

Indexed keywords

ANTINEOPLASTIC AGENT; CALGRANULIN A; CALGRANULIN B; CALVASCULIN; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; DENDRITIC CELL VACCINE; FRACTALKINE; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; PROTEIN S 100; PROTEIN S100B; PSORIASIN; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; ANTIINFLAMMATORY AGENT; AUTACOID;

AUTOCRINE EFFECT; BREAST CANCER; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; DISTANT METASTASIS; DRUG EFFECT; DRUG RESISTANCE; HUMAN; INFLAMMATION; LUNG CANCER; METASTASIS; METASTASIS POTENTIAL; NONHUMAN; PANCREAS ADENOCARCINOMA; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SHORT SURVEY; SOLID TUMOR; STOMACH CANCER; STROMA CELL; THYROID PAPILLARY CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; TUMOR VASCULARIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CHEMOKINES; HUMANS; INFLAMMATION MEDIATORS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, CHEMOKINE; S100 PROTEINS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84930819767     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.05.002     Document Type: Review

References (198)

1. Teicher B.A., Fricker S.P. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin. Cancer Res 2010, 16:2927-2931.
2. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
3. Kakinuma T., Hwang S.T. Chemokines, chemokine receptors, and cancer metastasis. J. Leukoc. Biol 2006, 79:639-651.
4. Müller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
5. Bresnick A.R., Weber D.J., Zimmer D.B. S100 proteins in cancer. Nat. Rev. Cancer 2015, 15:96-109.
6. Zimmer D.B., Cornwall E.H., Landar A., Song W. The S100 protein family: history, function, and expression. Brain Res. Bull 1995, 37:417-429.
7. Henry J., Toulza E., Hsu C.Y., Pellerin L., Balica S., Mazereeuw-Hautier J., et al. Update on the epidermal differentiation complex. Front. Biosci. (Landmark Ed) 2012, 17:1517-1532.
8. Lunde M.L., Roman E., Warnakulasuriya S., Mehrotra R., Laranne J., Vasstrand E.N., et al. Profiling of chromosomal changes in potentially malignant and malignant oral mucosal lesions from South and South-East Asia using array-comparative genomic hybridization. Cancer Genomics Proteomics 2014, 11:127-140.
9. Leclerc E., Fritz G., Vetter S.W., Heizmann C.W. Binding of S100 proteins to RAGE: an update. Biochim. Biophys. Acta 2009, 1793:993-1007.
10. Klingelhofer J., Moller H.D., Sumer E.U., Berg C.H., Poulsen M., Kiryushko D., et al. Epidermal growth factor receptor ligands as new extracellular targets for the metastasis-promoting S100A4 protein. FEBS J. 2009, 276:5936-5948.
11. Sneh A., Deol Y.S., Ganju A., Shilo K., Rosol T.J., Nasser M.W., et al. Differential role of psoriasin (S100A7) in estrogen receptor alpha positive and negative breast cancer cells occur through actin remodeling. Breast Cancer Res. Treat 2013, 138:727-739.
12. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat. Immunol 2011, 12:715-723.
13. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6:392-401.
14. Chen J., Yao Y., Gong C., Yu F., Su S., Chen J., et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 2011, 19:541-555.
15. Hu M., Peluffo G., Chen H., Gelman R., Schnitt S., Polyak K. Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:3372-3377.
16. Robinson B.D., Sica G.L., Liu Y.-F., Rohan T.E., Gertler F.B., Condeelis J.S., et al. Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin. Cancer Res 2009, 15:2433-2441.
17. Dhawan P., Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J. Leukoc. Biol 2002, 72:9-18.
18. Rouault C., Pellegrinelli V., Schilch R., Cotillard A., Poitou C., Tordjman J., et al. Roles of chemokine ligand-2 (CXCL2) and neutrophils in influencing endothelial cell function and inflammation of human adipose tissue. Endocrinol 2013, 154:1069-1079.
19. Rot A., von Andrian U.H. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol 2004, 22:891-928.
20. Acharyya S., Oskarsson T., Vanharanta S., Malladi S., Kim J., Morris P.G., et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012, 150:165-178.
21. Ijichi H., Chytil A., Gorska A.E., Aakre M.E., Bierie B., Tada M., et al. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J. Clin. Invest 2011, 121:4106-4117.
22. Raghuwanshi S.K., Smith N., Rivers E.J., Thomas A.J., Sutton N., Hu Y., et al. G protein-coupled receptor kinase 6 deficiency promotes angiogenesis, tumor progression, and metastasis. J. Immunol 2013, 190:5329-5336.
23. Nasser M.W., Raghuwanshi S.K., Grant D.J., Jala V.R., Rajarathnam K., Richardson R.M. Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer. J. Immunol 2009, 183:3425-3432.
24. Umansky V., Sevko A. Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron 2013, 6:169-177.
25. Fang W., Ye L., Shen L., Cai J., Huang F., Wei Q., et al. Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8. Carcinogenesis 2014, 35:1780-1787.
26. Fernandis A.Z., Prasad A., Band H., Klösel R., Ganju R.K. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 2004, 23:157-167.
27. Sun X., Cheng G., Hao M., Zheng J., Zhou X., Zhang J., et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 2010, 29:709-722.
28. Kang Y. Functional genomic analysis of cancer metastasis: biologic insights and clinical implications. Expert Rev. Mol. Diagn 2005, 5:385-395.
29. Chiang A.C., Massagué J. Molecular basis of metastasis. N. Engl. J. Med 2008, 359:2814-2823.
30. Yang J., Mani S.A., Weinberg R.A. Exploring a new twist on tumor metastasis. Cancer Res 2006, 66:4549-4552.
31. Petit I., Jin D., Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 2007, 28:299-307.
32. Wang J., Wang J., Dai J., Jung Y., Wei C.-L., Wang Y., et al. A glycolytic mechanism regulating an angiogenic switch in prostate cancer. Cancer Res 2007, 67:149-159.
33. Liu B.Y., Soloviev I., Chang P., Lee J., Huang X., Zhong C., et al. Stromal cell-derived factor-1/CXCL12 contributes to MMTV-Wnt1 tumor growth involving Gr1+ CD11b+ cells. PLoS ONE 2010, 5:e8611.
34. Ueno T., Toi M., Saji H., Muta M., Bando H., Kuroi K., et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res 2000, 6:3282-3289.
35. Saji H., Koike M., Yamori T., Saji S., Seiki M., Matsushima K., et al. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 2001, 92:1085-1091.
36. Nakashima E., Mukaida N., Kubota Y., Kuno K., Yasumoto K., Ichimura F., et al. Human MCAF gene transfer enhances the metastatic capacity of a mouse cachectic adenocarcinoma cell line in vivo. Pharm. Res 1995, 12:1598-1604.
37. Salcedo R., Ponce M.L., Young H.A., Wasserman K., Ward J.M., Kleinman H.K., et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000, 96:34-40.
38. Youngs S.J., Ali S.A., Taub D.D., Rees R.C. Chemokines induce migrational responses in human breast carcinoma cell lines. Int. J. Cancer 1997, 71:257-266.
39. Qian B.-Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R., et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475:222-225.
40. Arendt L.M., McCready J., Keller P.J., Baker D.D., Naber S.P., Seewaldt V., et al. Obesity promotes breast cancer by CCL2-mediated macrophage recruitment and angiogenesis. Cancer Res 2013, 73:6080-6093.
41. Wu Y., Li Y.-Y., Matsushima K., Baba T., Mukaida N. CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process. J. Immunol 2008, 181:6384-6393.
42. Sasaki S., Baba T., Shinagawa K., Matsushima K., Mukaida N. Crucial involvement of the CCL3-CCR5 axis-mediated fibroblast accumulation in colitis-associated carcinogenesis in mice. Int. J. Cancer 2014, 135:1297-1306.
43. Iida N., Nakamoto Y., Baba T., Kakinoki K., Li Y.-Y., Wu Y., et al. Tumor cell apoptosis induces tumor-specific immunity in a CC chemokine receptor 1-and 5-dependent manner in mice. J. Leukoc. Biol 2008, 84:1001-1010.
44. Soria G., Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008, 267:271-285.
45. Cheng J.W., Sadeghi Z., Levine A.D., Penn M.S., von Recum H.A., Caplan A.I., et al. The role of CXCL12 and CCL7 chemokines in immune regulation, embryonic development, and tissue regeneration. Cytokine 2014, 69:277-283.
46. Ngo V.N., Tang H.L., Cyster J.G. Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B cells. J. Exp. Med 1998, 188:181-191.
47. Kim C.H., Broxmeyer H.E. Chemokines: signal lamps for trafficking of T and B cells for development and effector function. J. Leukoc. Biol 1999, 65:6-15.
48. Kim C.H., Pelus L.M., White J.R., Broxmeyer H.E. Differential chemotactic behavior of developing T cells in response to thymic chemokines. Blood 1998, 91:4434-4443.
49. Kim C.H., Pelus L.M., White J.R., Applebaum E., Johanson K., Broxmeyer H.E. CKβ-11/macrophage inflammatory protein-3β/EBI1-ligand chemokine is an efficacious chemoattractant for T and B cells. J. Immunol 1998, 160:2418-2424.
50. Dieu M.-C., Vanbervliet B., Vicari A., Bridon J.-M., Oldham E., Aït-Yahia S., et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med 1998, 188:373-386.
51. Kim C.H., Pelus L.M., White J.R., Broxmeyer H.E. Macrophage-inflammatory protein-3β/EBI1-ligand chemokine/CKβ-11, a CC chemokine, is a chemoattractant with a specificity for macrophage progenitors among myeloid progenitor cells. J. Immunol 1998, 161:2580-2585.
52. Braun S.E., Chen K., Foster R.G., Kim C.H., Hromas R., Kaplan M.H., et al. The CC chemokine CKβ-11/MIP-3β/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J. Immunol 2000, 164:4025-4031.
53. Xuan W., Qu Q., Zheng B., Xiong S., Fan G.H. The chemotaxis of M1 and M2 macrophages is regulated by different chemokines. J. Leukoc. Biol 2015, 97:61-69.
54. Cyster J.G. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J. Exp. Med 1999, 189:447-450.
55. + T-cell costimulation via a DOCK2/Rac-dependent pathway. Blood 2009, 114:580-588.
56. Friedman R.S., Jacobelli J., Krummel M.F. Surface-bound chemokines capture and prime T cells for synapse formation. Nat. Immunol 2006, 7:1101-1108.
57. + T cells. Cell. Immunol 2004, 231:75-84.
58. Bazan J.F., Bacon K.B., Hardiman G., Wang W., Soo K., Rossi D., et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997, 385:640-644.
59. Corcione A., Ferretti E., Bertolotto M., Fais F., Raffaghello L., Gregorio A., et al. CX3CR1 is expressed by human B lymphocytes and meditates CX3CL1 driven chemotaxis of tonsil centrocytes. PLoS ONE 2009, 4:e8485.
60. 3 CR1, which mediates both leukocyte migration and adhesion. Cell 1997, 91:521-530.
61. Nishimura M., Umehara H., Nakayama T., Yoneda O., Hieshima K., Kakizaki M., et al. Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J. Immunol 2002, 168:6173-6180.
62. Tsang J.Y., Ni Y.-B., Chan S.-K., Shao M.-M., Kwok Y.-K., Chan K.-W., et al. CX3CL1 expression is associated with poor outcome in breast cancer patients. Breast Cancer Res. Treat 2013, 140:495-504.
63. Zheng J., Yang M., Shao J., Miao Y., Han J., Du J. Chemokine receptor CX3CR1 contributes to macrophage survival in tumor metastasis. Mol. Cancer 2013, 12:141.
64. Boye K., Maelandsmo G.M. S100A4 and metastasis: a small actor playing many roles. Am. J. Pathol 2010, 176:528-535.
65. Siddique H.R., Adhami V.M., Parray A., Johnson J.J., Siddiqui I.A., Shekhani M.T., et al. The S100A4 oncoprotein promotes prostate tumorigenesis in a transgenic mouse model regulating NFκB through the RAGE receptor. Genes Cancer 2013, 4:224-234.
66. Li Z.-H., Dulyaninova N.G., House R.P., Almo S.C., Bresnick A.R. S100A4 regulates macrophage chemotaxis. Mol. Biol. Cell 2010, 21:2598-2610.
67. Klingelhöfer J., Ambartsumian N.S., Lukanidin E.M. Expression of the metastasis-associated mts1 gene during mouse development. Dev. Dyn 1997, 210:87-95.
68. Haase-Kohn C., Wolf S., Herwig N., Mosch B., Pietzsch J. Metastatic potential of B16-F10 melanoma cells is enhanced by extracellular S100A4 derived from RAW264. 7 macrophages. Biochem. Biophys. Res. Commun 2014, 446:143-148.
69. Klingelhöfer J., Grum-Schwensen B., Beck M.K., Knudsen R.S.P., Grigorian M., Lukanidin E., et al. Anti-S100A4 antibody suppresses metastasis formation by blocking stroma cell invasion. Neoplasia 2012, 14:1260-1268.
70. Saleem M., Kweon M.-H., Johnson J.J., Adhami V.M., Elcheva I., Khan N., et al. S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:14825-14830.
71. Levett D., Flecknell P.A., Rudland P.S., Barraclough R., Neal D.E., Mellon J.K., et al. Transfection of S100A4 produces metastatic variants of an orthotopic model of bladder cancer. Am. J. Pathol 2002, 160:693-700.
72. Ambartsumian N.S., Grigorian M.S., Larsen I.F., Karlstrøm O., Sidenius N., Rygaard J., et al. Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene. Oncogene 1996, 13:1621-1630.
73. Xue C., Plieth D., Venkov C., Xu C., Neilson E.G. The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res 2003, 63:3386-3394.
74. Bettum I.J., Vasiliauskaite K., Nygaard V., Clancy T., Pettersen S.J., Tenstad E., et al. Metastasis-associated protein S100A4 induces a network of inflammatory cytokines that activate stromal cells to acquire pro-tumorigenic properties. Cancer Lett 2014, 344:28-39.
75. Grum-Schwensen B., Klingelhöfer J., Grigorian M., Almholt K., Nielsen B.S., Lukanidin E., et al. Lung metastasis fails in MMTV-PyMT oncomice lacking S100A4 due to a T-cell deficiency in primary tumors. Cancer Res 2010, 70:936-947.
76. Mandal S., Curtis L., Pind M., Murphy L.C., Watson P.H. S100A7 (psoriasin) influences immune response genes in human breast cancer. Exp. Cell Res 2007, 313:3016-3025.
77. Nasser M.W., Qamri Z., Deol Y.S., Ravi J., Powell C.A., Trikha P., et al. S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res 2012, 72:604-615.
78. Nasser M.W., Wani N., Ahirwar D.K., Powell C.A., Ravi J., Elbaz M.M., et al. RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment. Cancer Res 2015, 75:974-985.
79. Lapeire L., Hendrix A., Lambein K., Van Bockstal M., Braems G., Van den Broecke R., et al. Cancer-associated adipose tissue promotes breast cancer progression by paracrine Oncostatin M and JAK3/STAT3 signaling. Cancer Res 2014, 74:6806-6819.
80. Foell D., Wittkowski H., Vogl T., Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J. Leukoc. Biol 2007, 81:28-37.
81. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol 2001, 33:637-668.
82. Gebhardt C., Riehl A., Durchdewald M., Németh J., Fürstenberger G., Müller-Decker K., et al. RAGE signaling sustains inflammation and promotes tumor development. J. Exp. Med 2008, 205:275-285.
83. Cheng P., Corzo C.A., Luetteke N., Yu B., Nagaraj S., Bui M.M., et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med 2008, 205:2235-2249.
84. Sinha P., Okoro C., Foell D., Freeze H.H., Ostrand-Rosenberg S., Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol 2008, 181:4666-4675.
85. Lin J., Yang Q., Yan Z., Markowitz J., Wilder P.T., Carrier F., et al. Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells. J. Biol. Chem 2004, 279:34071-34077.
86. Rust R.R., Baldisseri D.M., Weber D.J. Structure of the negative regulatory domain of p53 bound to S100B (ββ). Nat. Struct. Mol. Biol 2000, 7:570-574.
87. Hiratsuka S., Watanabe A., Aburatani H., Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol 2006, 8:1369-1375.
88. Hiratsuka S., Watanabe A., Sakurai Y., Akashi-Takamura S., Ishibashi S., Miyake K., et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat. Cell Biol 2008, 10:1349-1355.
89. Hiratsuka S., Ishibashi S., Tomita T., Watanabe A., Akashi-Takamura S., Murakami M., et al. Primary tumours modulate innate immune signalling to create pre-metastatic vascular hyperpermeability foci. Nat. Commun 2013, 4:1853.
90. Vicari A.P., Caux C. Chemokines in cancer. Cytokine Growth Factor Rev 2002, 13:143-154.
91. Zlotnik A. Chemokines in neoplastic progression. Semin. Cancer Biol 2004, 14:181-185.
92. Murakami T., Cardones A.R., Hwang S.T. Chemokine receptors and melanoma metastasis. J. Dermatol. Sci 2004, 36:71-78.
93. Mantovani A., Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol 2010, 22:231-237.
94. Solinas G., Germano G., Mantovani A., Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol 2009, 86:1065-1073.
95. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266.
96. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004, 4:71-78.
97. Mantovani A., Marchesi F., Porta C., Sica A., Allavena P. Inflammation and cancer: breast cancer as a prototype. Breast 2007, 16:27-33.
98. + T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009, 16:91-102.
99. Mantovani A. Cancer: inflammation by remote control. Nature 2005, 435:752-753.
100. Martinez F.O., Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 2014, 6:13.
101. Vogel D.Y., Heijnen P.D., Breur M., de Vries H.E., Tool A.T., Amor S., et al. Macrophages migrate in an activation-dependent manner to chemokines involved in neuroinflammation. J. Neuroinflammation 2014, 11:23.
102. Gocheva V., Wang H.-W., Gadea B.B., Shree T., Hunter K.E., Garfall A.L., et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 2010, 24:241-255.
103. Elbaz M., Nasser M.W., Ravi J., Wani N.A., Ahirwar D.K., Zhao H., et al. Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway; novel anti-tumor mechanisms of cannabidiol in breast cancer. Mol. Oncol 2015, 9:906-919.
104. Coussens L.M., Tinkle C.L., Hanahan D., Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490.
105. Dirkx A.E., Oude Egbrink M.G., Wagstaff J., Griffioen A.W. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J. Leukoc. Biol 2006, 80:1183-1196.
106. Goswami S., Sahai E., Wyckoff J.B., Cammer M., Cox D., Pixley F.J., et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res 2005, 65:5278-5283.
107. Leek R.D., Talks K.L., Pezzella F., Turley H., Campo L., Brown N.S., et al. Relation of hypoxia-inducible factor-2α (HIF-2α) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res 2002, 62:1326-1329.
108. Gabrilovich D.I., Bronte V., Chen S.-H., Colombo M.P., Ochoa A., Ostrand-Rosenberg S., et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007, 67:425-426.
109. Peranzoni E., Zilio S., Marigo I., Dolcetti L., Zanovello P., Mandruzzato S., et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol 2010, 22:238-244.
110. Youn J.-I., Kumar V., Collazo M., Nefedova Y., Condamine T., Cheng P., et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat. Immunol 2013, 14:211-220.
111. De Palma M., Mazzieri R., Politi L.S., Pucci F., Zonari E., Sitia G., et al. Tumor-targeted interferon-α delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 2008, 14:299-311.
112. Fridlender Z.G., Sun J., Kim S., Kapoor V., Cheng G., Ling L., et al. Polarization of tumor-associated neutrophil phenotype by TGF-β: "N1" versus "N2" TAN. Cancer Cell 2009, 16:183-194.
113. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
114. Orimo A., Weinberg R.A. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006, 5:1597-1601.
115. Trimboli A.J., Cantemir-Stone C.Z., Li F., Wallace J.A., Merchant A., Creasap N., et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 2009, 461:1084-1091.
116. Mishra P.J., Mishra P.J., Humeniuk R., Medina D.J., Alexe G., Mesirov J.P., et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 2008, 68:4331-4339.
117. Butler J.M., Kobayashi H., Rafii S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat. Rev. Cancer 2010, 10:138-146.
118. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med 2001, 7:1194-1201.
119. Spring H., Schüler T., Arnold B., Hämmerling G.J., Ganss R. Chemokines direct endothelial progenitors into tumor neovessels. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:18111-18116.
120. Rossi D., Zlotnik A. The biology of chemokines and their receptors. Annu. Rev. Immunol 2000, 18:217-242.
121. Kamohara H., Takahashi M., Ishiko T., Ogawa M., Baba H. Induction of interleukin-8 (CXCL-8) by tumor necrosis factor-alpha and leukemia inhibitory factor in pancreatic carcinoma cells: impact of CXCL-8 as an autocrine growth factor. Int. J. Oncol 2007, 31:627-632.
122. Roy M., Richard J.F., Dumas A., Vallières L. CXCL1 can be regulated by IL-6 and promotes granulocyte adhesion to brain capillaries during bacterial toxin exposure and encephalomyelitis. J. Neuroinflammation 2012, 9:18.
123. Thu Y.M., Richmond A. NF-kappaB inducing kinase: a key regulator in the immune system and in cancer. Cytokine Growth Factor Rev 2010, 21:213-226.
124. Michielsen A.J., Hogan A.E., Marry J., Tosetto M., Cox F., Hyland J.M., et al. Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer. PLoS ONE 2011, 6:e27944.
125. Raghuwanshi S.K., Nasser M.W., Chen X., Strieter R.M., Richardson R.M. Depletion of β-arrestin-2 promotes tumor growth and angiogenesis in a murine model of lung cancer. J. Immunol 2008, 180:5699-5706.
126. Sharma B., Nawandar D.M., Nannuru K.C., Varney M.L., Singh R.K. Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis, and lung metastasis. Mol. Cancer Ther 2013, 12:799-808.
127. Nasser M.W., Marjoram R.J., Brown S.L., Richardson R.M. Cross-desensitization among CXCR1, CXCR2, and CCR5: role of protein kinase C-ε. J. Immunol 2005, 174:6927-6933.
128. Palacios-Arreola M.I., Nava-Castro K.E., Castro J.I., García-Zepeda E., Carrero J.C., Morales-Montor J. The role of chemokines in breast cancer pathology and its possible use as therapeutic targets. J. Immunol. Res 2014, 2014.
129. Nannuru K.C., Sharma B., Varney M.L., Singh R.K. Role of chemokine receptor CXCR2 expression in mammary tumor growth, angiogenesis and metastasis. J. Carcinog 2011, 10:40.
130. Singh S., Wu S., Varney M., Singh A.P., Singh R.K. CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelial cell proliferation, migration and capillary-like structure formation. Microvasc. Res 2011, 82:318-325.
131. Schraufstatter I.U., Chung J., Burger M. IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways. Am. J. Physiol. Lung Cell. Mol. Physiol 2001, 280:L1094-L1103.
132. Maxwell P.J., Neisen J., Messenger J., Waugh D.J. Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells. Oncotarget 2014, 5:4895-4908.
133. Highfill S.L., Cui Y., Giles A.J., Smith J.P., Zhang H., Morse E., et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med 2014, 6:237ra267.
134. Ginestier C., Liu S., Diebel M.E., Korkaya H., Luo M., Brown M., et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest 2010, 120:485-497.
135. Ratajczak M., Zuba-Surma E., Kucia M., Reca R., Wojakowski W., Ratajczak J. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 2006, 20:1915-1924.
136. Ma Q., Jones D., Borghesani P.R., Segal R.A., Nagasawa T., Kishimoto T., et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4-and SDF-1-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:9448-9453.
137. Kang H., Watkins G., Douglas-Jones A., Mansel R.E., Jiang W.G. The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer. Breast 2005, 14:360-367.
138. Sánchez-Martín L., Estecha A., Samaniego R., Sánchez-Ramón S., Vega M.Á., Sánchez-Mateos P. The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood 2011, 117:88-97.
139. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
140. Sheridan C., Kishimoto H., Fuchs R.K., Mehrotra S., Bhat-Nakshatri P., Turner C.H., et al. CD44+/CD24-breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006, 8:R59.
141. Wani N.A., Nasser M.W., Ahirwar D.K., Zhao H., Miao Z., Shilo K., et al. CXC motif chemokine 12/CXC chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment. Breast Cancer Res 2014, 16:R54.
142. Daly C., Rollins B.J. Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies. Microcirculation 2003, 10:247-257.
143. Yu J.L., Rak J.W. Host microenvironment in breast cancer development: inflammatory and immune cells in tumour angiogenesis and arteriogenesis. Breast Cancer Res 2003, 5:83-88.
144. Huang S., Singh R.K., Xie K., Gutman M., Berry K.K., Bucana C.D., et al. Expression of theJE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. Cancer Immunol. Immunother 1994, 39:231-238.
145. Monti P., Leone B.E., Marchesi F., Balzano G., Zerbi A., Scaltrini F., et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 2003, 63:7451-7461.
146. Lebrecht A., Grimm C., Lantzsch T., Ludwig E., Hefler L., Ulbrich E., et al. Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. Tumour Biol 2004, 25:14-17.
147. Bonapace L., Coissieux M.M., Wyckoff J., Mertz K.D., Varga Z., Junt T., et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 2014, 515:130-133.
148. He S., Wang L., Wu Y., Li D., Zhang Y. CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 induce anti-tumor immunity against gastric cancer ex vivo and in vivo. J. Exp. Clin. Cancer Res 2010, 29:37.
149. Azenshtein E., Luboshits G., Shina S., Neumark E., Shahbazian D., Weil M., et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 2002, 62:1093-1102.
150. Cook J., Hagemann T. Tumour-associated macrophages and cancer. Curr. Opin. Pharmacol 2013, 13:595-601.
151. Elbarghati L., Murdoch C., Lewis C.E. Effects of hypoxia on transcription factor expression in human monocytes and macrophages. Immunobiology 2008, 213:899-908.
152. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
153. Mi Z., Bhattacharya S.D., Kim V.M., Guo H., Talbot L.J., Kuo P.C. Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis 2011, 32:477-487.
154. Swamydas M., Ricci K., Rego S.L., Dreau D. Mesenchymal stem cell-derived CCL-9 and CCL-5 promote mammary tumor cell invasion and the activation of matrix metalloproteinases. Cell Adh. Migr 2013, 7:315-324.
155. Chang L.Y., Lin Y.C., Mahalingam J., Huang C.T., Chen T.W., Kang C.W., et al. Tumor-derived chemokine CCL5 enhances TGF-beta-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res 2012, 72:1092-1102.
156. Cambien B., Richard-Fiardo P., Karimdjee B.F., Martini V., Ferrua B., Pitard B., et al. CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRbeta in colorectal carcinoma. PLoS ONE 2011, 6:e28842.
157. Wang S.W., Liu S.C., Sun H.L., Huang T.Y., Chan C.H., Yang C.Y., et al. CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment. Carcinogenesis 2015, 36:104-114.
158. Mitra A.K., Zillhardt M., Hua Y., Tiwari P., Murmann A.E., Peter M.E., et al. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov 2012, 2:1100-1108.
159. Jung D.W., Che Z.M., Kim J., Kim K., Kim K.Y., Williams D. Tumor-stromal crosstalk in invasion of oral squamous cell carcinoma: a pivotal role of CCL7. Int. J. Cancer 2010, 127:332-344.
160. Rajaram M., Li J., Egeblad M., Powers R.S. System-wide analysis reveals a complex network of tumor-fibroblast interactions involved in tumorigenicity. PLoS Genet 2013, 9:e1003789.
161. Ichikawa M., Williams R., Wang L., Vogl T., Srikrishna G. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol. Cancer Res 2011, 9:133-148.
162. Lin Y., Sharma S., John M.S. CCL21 cancer immunotherapy. Cancers 2014, 6:1098-1110.
163. Hillinger S., Yang S., Batra R., Strieter R., Weder W., Dubinett S., et al. CCL19 reduces tumour burden in a model of advanced lung cancer. Br. J. Cancer 2006, 94:1029-1034.
164. Mashino K., Sadanaga N., Yamaguchi H., Tanaka F., Ohta M., Shibuta K., et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res 2002, 62:2937-2941.
165. Wiley H.E., Gonzalez E.B., Maki W., Wu M.-T., Hwang S.T. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J. Natl Cancer Inst 2001, 93:1638-1643.
166. Takekoshi T., Fang L., Paragh G., Hwang S. CCR7-expressing B16 melanoma cells downregulate interferon-γ-mediated inflammation and increase lymphangiogenesis in the tumor microenvironment. Oncogenesis 2012, 1:e9.
167. Pan Y., Lloyd C., Zhou H., Dolich S., Deeds J., Gonzalo J.-A., et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 1997, 387:611-616.
168. Marchesi F., Locatelli M., Solinas G., Erreni M., Allavena P., Mantovani A. Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer. J. Neuroimmunol 2010, 224:39-44.
169. Bochet L., Lehuédé C., Dauvillier S., Wang Y.Y., Dirat B., Laurent V., et al. Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. Cancer Res 2013, 73:5657-5668.
170. Cerezo L.A., Remakova M., Tomcik M., Gay S., Neidhart M., Lukanidin E., et al. The metastasis-associated protein S100A4 promotes the inflammatory response of mononuclear cells via the TLR4 signalling pathway in rheumatoid arthritis. Rheumatology (Oxford) 2014, 53:1520-1526.
171. Medapati M.R., Dahlmann M., Ghavami S., Pathak K.A., Lucman L., Klonisch T., et al. RAGE mediates the pro-migratory response of extracellular S100A4 in human thyroid cancer cells. Thyroid 2015, 25:514-527.
172. Hansen M.T., Forst B., Cremers N., Quagliata L., Ambartsumian N., Grum-Schwensen B., et al. A link between inflammation and metastasis: serum amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4. Oncogene 2015, 34:424-435.
173. Mælandsmo G.M., Hovig E., Skrede M., Engebraaten O., Flørenes V.A., Myklebost O., et al. Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme. Cancer Res 1996, 56:5490-5498.
174. Davies M., Rudland P.S., Robertson L., Parry E.W., Jolicoeur P., Barraclough R. Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours. Oncogene 1996, 13:1631-1637.
175. Roth J., Vogl T., Sorg C., Sunderkötter C. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol 2003, 24:155-158.
176. Goyette J., Geczy C.L. Inflammation-associated S100 proteins: new mechanisms that regulate function. Amino Acids 2011, 41:821-842.
177. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc. Res. Tech 2003, 60:540-551.
178. Marenholz I., Heizmann C.W., Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem. Biophys. Res. Commun 2004, 322:1111-1122.
179. Winningham-Major F., Staecker J.L., Barger S.W., Coats S., Van Eldik L.J. Neurite extension and neuronal survival activities of recombinant S100 beta proteins that differ in the content and position of cysteine residues. J. Cell Biol 1989, 109:3063-3071.
180. Millward T.A., Heizmann C.W., Schäfer B.W., Hemmings B.A. Calcium regulation of Ndr protein kinase mediated by S100 calcium-binding proteins. EMBO J. 1998, 17:5913-5922.
181. Arcuri C., Bianchi R., Brozzi F., Donato R. S100B increases proliferation in PC12 neuronal cells and reduces their responsiveness to nerve growth factor via Akt activation. J. Biol. Chem 2005, 280:4402-4414.
182. Zhang L., Liu W., Alizadeh D., Zhao D., Farrukh O., Lin J., et al. S100B attenuates microglia activation in gliomas: possible role of STAT3 pathway. Glia 2011, 59:486-498.
183. Wang H., Zhang L., Zhang I.Y., Chen X., Da Fonseca A., Wu S., et al. S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages. Clin. Cancer Res 2013, 19:3764-3775.
184. Ke C.-C., Liu R.-S., Suetsugu A., Kimura H., Ho J.H., Lee O.K., et al. In vivo fluorescence imaging reveals the promotion of mammary tumorigenesis by mesenchymal stromal cells. PLoS ONE 2013, 8:e69658.
185. Hoffman R.M., Yang M. Color-coded fluorescence imaging of tumor-host interactions. Nat. Protoc 2006, 1:928-935.
186. Yang M., Li L., Jiang P., Moossa A., Penman S., Hoffman R.M. Dual-color fluorescence imaging distinguishes tumor cells from induced host angiogenic vessels and stromal cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:14259-14262.
187. Yang M., Reynoso J., Jiang P., Li L., Moossa A.R., Hoffman R.M. Transgenic nude mouse with ubiquitous green fluorescent protein expression as a host for human tumors. Cancer Res 2004, 64:8651-8656.
188. Amoh Y., Yang M., Li L., Reynoso J., Bouvet M., Moossa A.R., et al. Nestin-linked green fluorescent protein transgenic nude mouse for imaging human tumor angiogenesis. Cancer Res 2005, 65:5352-5357.
189. Hoffman R.M. In vivo imaging with fluorescent proteins: the new cell biology. Acta Histochem 2004, 106:77-87.
190. Amoh Y., Li L., Yang M., Jiang P., Moossa A.R., Katsuoka K., et al. Hair follicle-derived blood vessels vascularize tumors in skin and are inhibited by doxorubicin. Cancer Res 2005, 65:2337-2343.
191. Yamauchi K., Tome Y., Yamamoto N., Hayashi K., Kimura H., Tsuchiya H., et al. Color-coded real-time subcellular fluorescence imaging of the interaction between cancer and host cells in live mice. Anticancer Res 2012, 32:39-43.
192. Suetsugu A., Hassanein M.K., Reynoso J., Osawa Y., Nagaki M., Moriwaki H., et al. The cyan fluorescent protein nude mouse as a host for multicolor-coded imaging models of primary and metastatic tumor microenvironments. Anticancer Res 2012, 32:31-38.
193. Suetsugu A., Osawa Y., Nagaki M., Saji S., Moriwaki H., Bouvet M., et al. Imaging the recruitment of cancer-associated fibroblasts by liver-metastatic colon cancer. J. Cell. Biochem 2011, 112:949-953.
194. Suetsugu A., Osawa Y., Nagaki M., Moriwaki H., Saji S., Bouvet M., et al. Simultaneous color-coded imaging to distinguish cancer "stem-like" and non-stem cells in the same tumor. J. Cell. Biochem 2010, 111:1035-1041.
195. Hayashi K., Yamauchi K., Yamamoto N., Tsuchiya H., Tomita K., Bouvet M., et al. A color-coded orthotopic nude-mouse treatment model of brain-metastatic paralyzing spinal cord cancer that induces angiogenesis and neurogenesis. Cell Prolif 2009, 42:75-82.
196. Dilloo D., Bacon K., Holden W., Zhong W., Burdach S., Zlotnik A., et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat. Med 1996, 2:1090-1095.
197. Emtage P., Wan Y., Hitt M., Graham F., Muller W., Zlotnik A., et al. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum. Gene Ther 1999, 10:697-709.
198. Homey B., Müller A., Zlotnik A. Chemokines: agents for the immunotherapy of cancer?. Nat. Rev. Immunol 2002, 2:175-184.